Grace Therapeutics Inc (GRCE) Stock Price, Quote & News

Company Profile

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain as...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 322 1602

Website: www.gracetx.com

Address:

103 Carnegie Center, Suite 300, Princeton, United States

deweyeggbert Jul. 3 at 11:32 PM

$GRCE $5 is the floor. I'll decide my next move thereafter.

0 · Reply

CharlieeMungerTWITS Jul. 2 at 5:07 PM

$GRCE

0 · Reply

ccledez Jul. 2 at 4:42 PM

$GRCE bio seems like safe haven. 😂 Hope you bought at 2.25 Going over $5 soon .

2 · Reply

BB_88_ Jul. 2 at 4:10 PM

$GRCE send it

0 · Reply

VCV86 Jul. 2 at 2:59 PM

$UNCY $CING $ACHV if you like post-CMC CRL setups, $GRCE looks like a great opportunity here. The stock has been hammered, and FDA alignment after the Type A meeting could come anytime.

3 · Reply

deweyeggbert Jul. 2 at 2:28 PM

$GRCE added more shares.

0 · Reply

ccledez Jul. 2 at 1:10 PM

$UNCY $CING Don't forget about $GRCE Same playbook.

0 · Reply

ccledez Jul. 2 at 8:22 AM

$GRCE based on perfect execution And based on total addressable market Gemini says this could reach $80 per share

1 · Reply

alexpitti Jul. 2 at 1:38 AM

it's extremely likely the fda meeting happened at the end of june or in early july, but then we must wait for the minutes $GRCE

1 · Reply

CharlieeMungerTWITS Jul. 2 at 12:37 AM

$UNCY haha same as $GRCE ! Always buy them CRL manufacturing rejections as low as you can

0 · Reply

Grace Therapeutics reports FY26 EPS (47c) vs (79c) last year

Jun 18, 2026, 8:00 AM EDT - 16 days ago

Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update

Jun 18, 2026, 7:00 AM EDT - 16 days ago

Grace Therapeutics Annual report: Q4 2026

Jun 18, 2026, 7:00 AM EDT - 16 days ago

Grace Therapeutics Earnings release: Q4 2026

Jun 18, 2026, 7:00 AM EDT - 16 days ago

Grace Therapeutics Slides: Corporate presentation

2026-04-24T13:31:53.000Z - 2 months ago

Grace Therapeutics price target lowered to $4 from $11 at Craig-Hallum

2026-04-24T12:03:06.000Z - 2 months ago

Grace Therapeutics price target lowered to $8 from $12 at TD Cowen

2026-04-23T17:55:47.000Z - 2 months ago

Grace Therapeutics down 48% after receipt of CRL from FDA for GTx-104

2026-04-23T17:52:41.000Z - 2 months ago

Grace Therapeutics, Inc trading resumes

Apr 23, 2026, 1:25 PM EDT - 2 months ago

US FDA declines to approve Grace Therapeutics' drug for a type of stroke

2026-04-23T17:21:26.000Z - 2 months ago

Grace Therapeutics issued Complete Response Letter from FDA

Apr 23, 2026, 1:13 PM EDT - 2 months ago

Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104

2026-04-23T16:30:22.000Z - 2 months ago

Grace Therapeutics, Inc trading halted, news pending

Apr 14, 2026, 8:00 AM EDT - 2 months ago

Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026

Mar 19, 2026, 8:00 AM EDT - 3 months ago

Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences

Mar 4, 2026, 10:30 AM EST - 4 months ago

Grace Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 8:00 AM EST - 4 months ago

Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 13, 2026, 6:00 AM EST - 5 months ago

Grace Therapeutics Slides: Corporate presentation

Feb 12, 2026, 4:00 PM EST - 5 months ago

Grace Therapeutics Earnings release: Q3 2026

Feb 12, 2026, 4:00 PM EST - 5 months ago

Grace Therapeutics Quarterly report: Q3 2026

2026-02-12T13:08:12.000Z - 5 months ago

Grace Therapeutics reports Q3 EPS (14c) vs (36c) last year

Feb 12, 2026, 8:00 AM EST - 5 months ago

Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update

Nov 30, 2025, 4:00 PM EST - 7 months ago

Grace Therapeutics Slides: Corporate Presentation

Nov 17, 2025, 8:00 AM EST - 8 months ago

Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference

2025-11-13T13:10:34.000Z - 8 months ago

Grace Therapeutics reports Q2 EPS (6c) vs (30c) last year

Nov 13, 2025, 8:00 AM EST - 8 months ago

Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update

Nov 13, 2025, 7:00 AM EST - 8 months ago

Grace Therapeutics Earnings release: Q2 2026

Nov 13, 2025, 7:00 AM EST - 8 months ago

Grace Therapeutics Quarterly report: Q2 2026

Nov 11, 2025, 8:30 AM EST - 8 months ago

Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting

2025-10-23T12:15:45.000Z - 9 months ago

Grace Therapeutics secures $4M through common warrant exercises

Oct 23, 2025, 8:00 AM EDT - 9 months ago

Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review

2025-09-22T12:21:05.000Z - 10 months ago

Grace Therapeutics announces presentation of Phase 3 STRIVE-ON safety trial

Sep 22, 2025, 8:00 AM EDT - 10 months ago

Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting

2025-09-18T12:41:21.000Z - 10 months ago

Grace granted sixth U.S. patent covering I.V. dosing regimen for GTx-104

Sep 18, 2025, 8:30 AM EDT - 10 months ago

Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104

Sep 16, 2025, 3:30 PM EDT - 10 months ago

Grace Therapeutics Transcript: Q3 Investor Summit Group Virtual Conference 2025

Sep 4, 2025, 8:00 AM EDT - 10 months ago

Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference

2025-08-27T12:06:17.000Z - 11 months ago

Grace Therapeutics announces U.S. FDA accepted NDA for GTx-104 for review

Aug 27, 2025, 8:00 AM EDT - 11 months ago

Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104

Aug 27, 2025, 7:00 AM EDT - 11 months ago

Grace Therapeutics Slides: Corporate Presentation

Aug 12, 2025, 4:00 PM EDT - 11 months ago

Grace Therapeutics Earnings release: Q1 2026

Aug 12, 2025, 4:00 PM EDT - 11 months ago

Grace Therapeutics Quarterly report: Q1 2026

2025-08-12T12:10:54.000Z - 11 months ago

Grace Therapeutics reports Q1 EPS (21c) vs (24c) last year

Aug 12, 2025, 8:00 AM EDT - 11 months ago

Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update

Jul 28, 2025, 8:00 AM EDT - 1 year ago

Grace Therapeutics Proxy statement: Proxy Filing

Jul 28, 2025, 8:00 AM EDT - 1 year ago

Grace Therapeutics Proxy statement: Proxy Filing

2025-07-17T17:05:36.000Z - 1 year ago

Grace Therapeutics management to meet virtually with Craig-Hallum

2025-06-25T12:05:35.000Z - 1 year ago

Grace Therapeutics announces submission to U.S. FDA of NDA for GTx-104

Jun 25, 2025, 8:00 AM EDT - 1 year ago

Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104

Jun 23, 2025, 8:00 AM EDT - 1 year ago

Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update

Jun 23, 2025, 7:00 AM EDT - 1 year ago

Grace Therapeutics Earnings release: Q4 2025

Jun 23, 2025, 7:00 AM EDT - 1 year ago

Grace Therapeutics Annual report: Q4 2025

Jun 13, 2025, 8:00 AM EDT - 1 year ago

Grace Therapeutics to Participate in the 2025 BIO International Conference

Apr 9, 2025, 8:00 AM EDT - 1 year ago

Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104

Mar 11, 2025, 7:00 AM EDT - 1 year ago

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

MTNB

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Grace Therapeutics Registration statement: Registration Filing

Mar 4, 2025, 2:30 PM EST - 1 year ago

Grace Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 25, 2025, 8:00 AM EST - 1 year ago

Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 13, 2025, 8:00 AM EST - 1 year ago

Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update

Feb 12, 2025, 6:00 PM EST - 1 year ago

Grace Therapeutics Quarterly report: Q3 2025

Feb 12, 2025, 6:00 PM EST - 1 year ago

Grace Therapeutics Earnings release: Q3 2025

Feb 10, 2025, 8:05 AM EST - 1 year ago

Grace Therapeutics Announces Private Placement Financing of up to $30 Million

Feb 10, 2025, 8:01 AM EST - 1 year ago

Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH

Jan 7, 2025, 8:00 AM EST - 1 year ago

Grace Therapeutics to Participate in Upcoming Investor Events January 2025

Nov 20, 2024, 2:00 PM EST - 1 year ago

Grace Therapeutics Transcript: KOL Event

Nov 13, 2024, 12:00 AM EST - 1 year ago

Grace Therapeutics Quarterly report: Q2 2025

Nov 13, 2024, 12:00 AM EST - 1 year ago

Grace Therapeutics Earnings release: Q2 2025

Oct 25, 2024, 8:00 AM EDT - 1 year ago

Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.

Sep 25, 2024, 7:30 AM EDT - 1 year ago

Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104

Sep 19, 2024, 12:30 PM EDT - 1 year ago

Grace Therapeutics Transcript: Life Sciences Investor Forum 2024

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Grace Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 6, 2024, 8:00 AM EDT - 1 year ago

Grace Therapeutics Proxy statement: Proxy Filing

Sep 5, 2024, 10:35 AM EDT - 1 year ago

Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 9, 2024, 8:00 AM EDT - 2 years ago

Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update

Aug 9, 2024, 7:31 AM EDT - 2 years ago

Grace Therapeutics Quarterly report: Q1 2025

Aug 7, 2024, 8:00 AM EDT - 2 years ago

Grace Therapeutics Proxy statement: Proxy Filing

Jun 27, 2024, 4:05 PM EDT - 2 years ago

Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial

Jun 21, 2024, 8:00 AM EDT - 2 years ago

Acasti Announces Year-End 2024 Financial Results, Provides Business Update

Jun 21, 2024, 7:00 AM EDT - 2 years ago

Grace Therapeutics Annual report: Q4 2024

Jun 21, 2024, 7:00 AM EDT - 2 years ago

Grace Therapeutics Earnings release: Q4 2024

May 28, 2024, 4:05 PM EDT - 2 years ago

Acasti Pharma to Attend BIO International Convention 2024

Feb 12, 2024, 8:00 AM EST - 2 years ago

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights

Feb 12, 2024, 7:00 AM EST - 2 years ago

Grace Therapeutics Quarterly report: Q3 2024

Feb 12, 2024, 7:00 AM EST - 2 years ago

Grace Therapeutics Earnings release: Q3 2024

Feb 1, 2024, 8:00 AM EST - 2 years ago

Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial

Dec 13, 2023, 8:00 AM EST - 2 years ago

Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024

Nov 13, 2023, 8:00 AM EST - 2 years ago

Acasti Announces Second Quarter 2024 Financial Results and Business Highlights

Nov 13, 2023, 7:00 AM EST - 2 years ago

Grace Therapeutics Quarterly report: Q2 2024

Nov 13, 2023, 7:00 AM EST - 2 years ago

Grace Therapeutics Earnings release: Q2 2024

Oct 23, 2023, 8:00 AM EDT - 2 years ago

Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial

Oct 6, 2023, 8:00 AM EDT - 2 years ago

Grace Therapeutics Registration statement: Registration Filing

Oct 4, 2023, 8:00 AM EDT - 2 years ago

Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)

Sep 26, 2023, 8:00 AM EDT - 3 years ago

Acasti Announces $7.5 Million Private Placement Equity Financing

Sep 6, 2023, 8:00 AM EDT - 3 years ago

Acasti to Participate in the H.C. Wainwright Global Investment Conference

Aug 25, 2023, 8:00 AM EDT - 3 years ago

Grace Therapeutics Proxy statement: Proxy Filing

Aug 25, 2023, 8:00 AM EDT - 3 years ago

Grace Therapeutics Proxy statement: Proxy Filing

Aug 11, 2023, 9:30 AM EDT - 3 years ago

Grace Therapeutics Quarterly report: Q1 2024

Aug 11, 2023, 9:30 AM EDT - 3 years ago

Grace Therapeutics Earnings release: Q1 2024

Aug 11, 2023, 7:00 AM EDT - 3 years ago

Acasti Announces First Quarter 2024 Financial Results and Business Highlights

Aug 9, 2023, 4:05 PM EDT - 3 years ago

Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting

Jul 10, 2023, 9:00 AM EDT - 3 years ago

Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients

Jul 7, 2023, 8:00 AM EDT - 3 years ago

Acasti Pharma Announces 1-for-6 Reverse Stock Split

Jul 5, 2023, 9:00 AM EDT - 3 years ago

Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023

deweyeggbert Jul. 3 at 11:32 PM

$GRCE $5 is the floor. I'll decide my next move thereafter.

0 · Reply

CharlieeMungerTWITS Jul. 2 at 5:07 PM

$GRCE

0 · Reply

ccledez Jul. 2 at 4:42 PM

$GRCE bio seems like safe haven. 😂 Hope you bought at 2.25 Going over $5 soon .

2 · Reply

BB_88_ Jul. 2 at 4:10 PM

$GRCE send it

0 · Reply

VCV86 Jul. 2 at 2:59 PM

$UNCY $CING $ACHV if you like post-CMC CRL setups, $GRCE looks like a great opportunity here. The stock has been hammered, and FDA alignment after the Type A meeting could come anytime.

3 · Reply

deweyeggbert Jul. 2 at 2:28 PM

$GRCE added more shares.

0 · Reply

ccledez Jul. 2 at 1:10 PM

$UNCY $CING Don't forget about $GRCE Same playbook.

0 · Reply

ccledez Jul. 2 at 8:22 AM

$GRCE based on perfect execution And based on total addressable market Gemini says this could reach $80 per share

1 · Reply

alexpitti Jul. 2 at 1:38 AM

it's extremely likely the fda meeting happened at the end of june or in early july, but then we must wait for the minutes $GRCE

1 · Reply

CharlieeMungerTWITS Jul. 2 at 12:37 AM

$UNCY haha same as $GRCE ! Always buy them CRL manufacturing rejections as low as you can

0 · Reply

CharlieeMungerTWITS Jul. 1 at 2:47 PM

$GRCE $2.48 pre market ?! The algos are setting hints

0 · Reply

RomuloSkagen Jun. 30 at 11:53 PM

$GRCE after seeing what happened to UNCY today, I’m not taking CMC issues lightly. Got burned on both. FDA needs to get their act together.

1 · Reply

MZ2X Jun. 30 at 8:16 PM

$GRCE thinking about adding more here, type a meeting PR could be any day this month

1 · Reply

VCV86 Jun. 30 at 3:32 PM

$GRCE Easy money here. 20k shares, expecting the PR after the FDA meeting anytime.

0 · Reply

CharlieeMungerTWITS Jun. 30 at 12:59 AM

$GRCE buyer here. CRL response and resubmission for PDUFA inbound. I’ll deposit $50K here. See you in 8 months at $4 + @GangsterX

0 · Reply

alexpitti Jun. 29 at 10:21 PM

explain to me what idiot would puke their shares randomly? just sell 1/4th every week. why tank it? $GRCE

0 · Reply

D3fiant Jun. 29 at 7:02 PM

$GRCE added [email protected]

0 · Reply

WolfOf_MyStreet Jun. 29 at 6:53 PM

$GRCE stop loss harvesting at it's finest.

0 · Reply

MZ2X Jun. 29 at 6:52 PM

$GRCE didnt even have the chance to buy that dip lol

0 · Reply

CharlieeMungerTWITS Jun. 29 at 6:42 PM

$GRCE thinly traded

0 · Reply

SDN_General Jun. 29 at 6:35 PM

$GRCE wtf

1 · Reply

Stockseeking Jun. 27 at 3:36 AM

$GRCE >4 after alignment with FDA on resubmission soon (<2 months)

0 · Reply

Market Cap	38.57M
Revenue (ttm)	0.00
Net Income (ttm)	-7.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	268,900
Avg Vol	578,950
Day's Range	N/A - N/A
Shares Out	16.27M
Stochastic %K	72%
Beta	0.37
Analysts	Strong Sell
Price Target	$8.17